ÂÒÂ×Ðã presentations at The Union annual conference,Ìý15-18 Nov 2023
conference is a major TB research and policy event.Ìý
Below are presentations by ÂÒÂ×Ðã-TB affiliated people. All timings are CET.
Wednesday 15th November | |||
Ibrahim AbubakarÌý Ìý | Panel discussionÌý | WHO Global #EndTB Symposium 2023 Ìý Panel discussion: Breakthroughs and opportunities to accelerate the TB responseÌý | Wednesday, 15 Nov 2023, 10:30 - 11:20Ìý |
Helgard Claassen/ Al LeslieÌý | Oral presentationÌý | OA02 Subclinical TB: How to recognize it when you see it?Ìý D1: TB epidemiology across the life courseÌý Ìý Ìý OA02-213-15 3-year outcomes in individuals with microbiologically proven sub-clinical TB detected in a population-based survey in rural KwaZulu-Natal, South Africa Ìý | Wednesday, 15 Nov 2023Ìý 11:14 - 11:23Ìý Ìý |
Ibrahim AbubakarÌý | PlenaryÌý | PL-01 Closing the gap between evidence and implementationÌý | Wednesday, 15 Nov 2023, 12:00 - 13:00Ìý Ìý Ìý |
Gareth HughesÌý | Oral presentationÌý Ìý | OA06 Safety of regimens for R-RÌý B3: Clinical trials and operational research for new treatments for TB (for adults and children)Ìý Ìý OA06-243-15 Predictive analyses of QT prolongation from ECG monitoring in the STREAM Stage 2 trialÌý | Wednesday, 15 Nov 2023Ìý 15:37 - 15:45Ìý |
Angela CrookÌý | SymposiaÌý | SP06 Progress and innovation in developing shorter treatment regimens for people with TBÌý B3: Clinical trials and operational research for new treatments for TB (for adults and children)Ìý Ìý Duration-ranging in Phase 2 trials: UNITE4TB and the MAMS-ROCI DesignÌý | Wednesday, 15 Nov 2023Ìý 15:47 - 16:01Ìý |
Andrew NunnÌý | ChairÌý | OA07 Treatment outcome of all oral-short course regimens for RR.TBÌý B3: Clinical trials and operational research for new treatments for TB (for adults and children)Ìý | Wednesday, 15 Nov 2023Ìý 16:45 - 18:15Ìý |
Al StoryÌý | SymposiaÌý | SP10 Providing people-centred TB care for vulnerable populationsÌý E2: Key affected populations: behavioural, social, and cultural issues and contextsÌý Ìý Active case-finding and differentiated care models to accelerate TB elimination among key affected populations in Delhi, IndiaÌý | Wednesday, 15 Nov 2023Ìý 17:04 - 17:18Ìý |
Ruth GoodallÌý | Oral presentationÌý Ìý | OA07 Treatment outcome of all oral-short course regimens for RR.TBÌý B3: Clinical trials and operational research for new treatments for TB (for adults and children)Ìý Ìý OA07-252-15 Long-term outcomes in STREAM Stage 2: A phase 3 trial in rifampicin-resistant TBÌý Ìý | Wednesday, 15 Nov 2023Ìý 17:26 - 17:35Ìý |
Thursday 16th November | |||
Jess PotterÌý | Union Side SessionÌý | Union Side Session: Partnering with Policymakers to Implement UNHLM 2023Ìý Ìý 08:20 - 08:40 Panel 1: Building a diverse community of advocatesÌý | Thursday, 16 Nov 2023 08:00 - 10:00 CETÌý |
Jess PotterÌý | Community ConnectÌý | CC-09 Reflecting and learning from community, academic and health professional engagement with the UN High-Level Meeting on TB for actionable next stepsÌý Track 3: Political contexts for community led advocacy and accountability Ìý Ìý Using our voice to call for change – an academic and health professional's perspectiveÌý | Thursday, 16 Nov 2023Ìý 10:45 - 10:55Ìý |
Gabriele Pollara | TB Science | Altered interleukin-6 signalling and risk of TB disease: a meta-analysis and trans-ancestry Mendelian randomisation study | Thursday, 16 Nov 2023Ìý 11:05 - 11:10,ÌýSalle Maillot 5 |
Sanjib Bhakta | TB Science | TBS2C: Host-directed therapyÌý Anti-inflammatory drugs for TB | Thursday, 16 Nov 2023Ìý 17.13 - 17.23 |
Friday 17th November | |||
Asad ZaidiÌý | SymposiaÌý Ìý | SP28 An International Consensus on Early TB (ICE-TB) - the path to programmatic impactÌý C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)Ìý Ìý An International Consensus for Early TB (ICE-TB): Results from the 1st Early TB SymposiumÌý | Friday, 17 Nov 2023Ìý 10:20 - 10:32Ìý |
Hanif EsmailÌý | SymposiaÌý | SP28 An International Consensus on Early TB (ICE-TB) - the path to programmatic impactÌý C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)Ìý Ìý Interventions for early TB: Developing interventions for a new frameworkÌý | Friday, 17 Nov 2023Ìý 10:57 - 11:10Ìý |
Gabriele PollaraÌý | E-posterÌý | EP17 Immunology for early TB diagnosisÌý A1: Immunology - research into diagnostics and immunityÌý Ìý EP17-1153-17 Altered interleukin-6 signalling and risk of TB disease: A meta-analysis and Mendelian randomisation studyÌý | Friday, 17 Nov 2023Ìý 12:55 - 13:00ÌýSalle Maillot 1 |
Ankur Gupta-WrightÌý | SymposiaÌý | SP36 New tests for TB screening, diagnosis and treatment monitoring: what do we need?Ìý A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developmentsÌý Ìý Patient-pathway analysis of TB treatment monitoringÌý | Friday, 17 Nov 2023Ìý 16:01 - 16:15Ìý |
Hanif EsmailÌý | Satellite sessionÌý | SS17 Rethinking clinical trial design to accelerate improved treatment options for TB-affected communities: Innovative collaborations redefining TB drug and regimen developmentÌý B3: Clinical trials and operational research for new treatments for TB (for adults and children)Ìý UNITE4TB-01: A new PARADIGM of evaluating novel drugsÌý | Friday, 17 Nov 2023Ìý Session:Ìý18:30 – 20:00 18:49 - 18:56Ìý |
Saturday 18th November | |||
Stella Fabiane | Oral presentationÌý | OA59 TB control: from diagnosis to treatment outcome OA59-667-18 Does the choice of fluoroquinolone affect treatment outcomes in rifampicin-resistant TB? | Saturday, 18 Nov 2023Ìý 08:11Ìý- 08:20Ìý |
Ruth GoodallÌý Ìý | Oral presentationÌý Ìý | OA59 TB control: from diagnosis to treatment outcomeÌý C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)Ìý Ìý OA59-663-18 Creating a global individual patient data platform for TB treatment, TB-IPDÌý | Saturday, 18 Nov 2023Ìý 08:35 - 08:44Ìý |
Ìý
Ìý